Aerovate Therapeutics Stock Downgraded After Trial Setback
Aerovate Therapeutics stock downgraded by BTIG after AV-101 trial setback; mixed analyst views and future pivotal readouts crucial for investors.
- Latest
- Trending
Aerovate Therapeutics stock downgraded by BTIG after AV-101 trial setback; mixed analyst views and future pivotal readouts crucial for investors.
Avidity Biosciences sees share ownership shift as MacLean reduces holding under Rule 10b5-1 Plan; positive sector developments bolster outlook.
Arthur A. Levin sells 40K Avidity shares; BofA ups target to $45 as FDA advances myotonic dystrophy treatment. AI-assisted article ...
Morgan Stanley suggests credit trouble may arise if the Fed hikes rates, as spreads widen for US investment-grade debt while ...
Two major US banks are experiencing billions of dollars in deposit outflows, while other regional banks do not face the ...
JPMorgan CEO Jamie Dimon, BlackRock's Larry Fink, and Blackstone's Steve Schwarzman express concerns about fear and uncertainty in markets. Dimon ...
Warren Buffett's favorite stock, Wells Fargo, has potential for income investors. The bank's recent improvements make it worth considering for ...
Taiwan Semi's stock tumbled 5% and finished below its 50-day moving average. However, it snapped a four-quarter slump in its ...
The SCRA protects service members from high interest rates on pre-deployment debts. Wells Fargo has not responded to the allegations.
The market's short-term trajectory will be influenced by various developments, according to expert Matt Hougan. Despite uncertainties, he remains optimistic ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.